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Natural products harbor unique and complex structures that provide
valuable antibiotic scaffolds. With an increase in antibiotic resis-
tance, natural products once again hold promise for new antimi-
crobial therapies, especially those with unique scaffolds that have
been overlooked due to a lack of understanding of how they
function. Dithiolopyrrolones (DTPs) are an underexplored class of
disulfide-containing natural products, which exhibit potent anti-
microbial activities against multidrug-resistant pathogens. DTPs
were thought to target RNA polymerase, but conflicting observa-
tions leave the mechanisms elusive. Using a chemical genomics
screen in Escherichia coli, we uncover a mode of action for DTPs—
the disruption of metal homeostasis. We show that holomycin, a
prototypical DTP, is reductively activated, and reduced holomycin
chelates zinc with high affinity. Examination of reduced holomycin
against zinc-dependent metalloenzymes revealed that it inhibits
E. coli class II fructose bisphosphate aldolase, but not RNA polymer-
ase. Reduced holomycin also strongly inhibits metallo–β-lactamases
in vitro, major contributors to clinical carbapenem resistance, by
removing active site zinc. These results indicate that holomycin is
an intracellular metal-chelating antibiotic that inhibits a subset of
metalloenzymes and that RNA polymerase is unlikely to be the
primary target. Our work establishes a link between the chemical
structures of DTPs and their antimicrobial action; the ene-dithiol
group of DTPs enables high-affinity metal binding as a central
mechanism to inhibit metabolic processes. Our study also validates
the use of chemical genomics in characterizing modes of actions of
antibiotics and emphasizes the potential of metal-chelating natu-
ral products in antimicrobial therapy.
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Studies on the mode of action of natural products have un-covered valuable antimicrobial targets and provided starting
points for the design of new antibiotics (1). Although consider-
able effort is directed toward discovering novel natural products
as next-generation antibiotics, many “old” classes of natural prod-
ucts remain underexplored and unused. As we show here, a more
complete understanding of the mode of action of these neglected
natural products could provide novel antimicrobial targets and re-
vive the potential of these compounds as therapeutics.
Dithiolopyrrolone (DTP) natural products display broad-
spectrum inhibitory activity against bacteria, fungi, and human
cell lines (2). DTPs are active against both Gram-negative and
Gram-positive pathogens, with high potency against methicillin-
resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae,
and Pseudomonas aeruginosa. Members of the DTP family share
a unique bicyclic core consisting of a dihydropyrrolone ring fused
to an ene-disulfide, with a variety of N-acyl groups (2, 3); hol-
omycin and thiolutin contain an N-acetyl group (Fig. 1A), whereas
thiomarinol has the polyketide antibiotic marinolic acid as the
N-acyl group linked to the DTP (4, 5).
The promising antimicrobial activity of DTPs has prompted
several studies of their mode of action. Holomycin and thiolutin
have been examined against Escherichia coli and Saccharomyces
cerevisiae, with conflicting results. Thiolutin reversibly inhibits
RNA and protein synthesis in both E. coli and S. cerevisiae in
whole-cell assays and inactivates yeast RNA transcription
in vitro; thus, RNA polymerase was proposed as the primary
target in yeast (6, 7). Oliva et al. confirmed inhibition of growth
and macromolecule synthesis in E. coli (8). However, they found
holomycin only weakly inhibited E. coli RNA polymerase
in vitro, shedding doubts on RNA polymerase being the primary
target in E. coli (8). Glucose utilization and respiration in E. coli
have also been shown to be inhibited by thiolutin (9). Given this
conflicting evidence, the mode of action for this intriguing class
of antibiotics is unclear.
We wondered whether the DTP scaffold might impact multi-
ple pathways that contribute to its overall antimicrobial effect.
Earlier work showed that the ene-disulfide of holomycin is redox-
active and integral to its antimicrobial action (Fig. 1B) (10, 11).
The producing bacterium encodes a dithiol oxidase HlmI in the
holomycin biosynthetic pathway to keep the ene-disulfide closed
for self-protection against the ene-dithiol form (11). The hlmI
deletion mutant generates S,S’-dimethylated reduced holomycin
with no antimicrobial activity (Fig. 1B) as a backup self-protection
mechanism (10). These results suggest that holomycin is a prodrug
whose activation involves intracellular reduction of the ene-
disulfide to the active form ene-dithiol (Fig. 1B). The mechanism
by which reduced holomycin (red-holomycin) inhibits bacterial
growth and the role of the ene-dithiol group remain unknown.
To identify the pathways that DTPs may inhibit, we used a
powerful chemical genomics platform in E. coli that profiles global
drug–gene interactions (12). In the original screen, the Keio col-
lection of 3,900 nonessential E. coli K-12 gene knockouts was
screened against varying dosages of 114 antibiotics and chemical
and physical stressors, yielding 324 conditions (12, 13). Here, we
applied this platform to gain a global view of cellular pathways
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affected by the antibiotics holomycin and thiolutin as well as
gliotoxin, a fungal toxin that is also thought to function via a
redox-active disulfide (Fig. 1A) (14). Our screen identified a
role for all three compounds in disrupting metal homeostasis.
Our mode of action studies on holomycin as a prototypical
DTP reveal that holomycin is an intracellular metallophore
with high affinity for metal ions, especially zinc, and can inhibit
a subset of zinc-dependent metalloenzymes. Our work provides
a model for the function of holomycin and related DTPs
as antibiotics.
Results and Discussion
A Unique Sensitivity Profile for Holomycin, Thiolutin, and Gliotoxin.
To gain insights into the mode of action for holomycin, thiolutin,
and gliotoxin, we investigated these compounds in a chemical
genomics screen in E. coli K-12 with other neglected antibiotics
for a total of 51 unique conditions (15). Mutants from the Keio
deletion library were grown as individual colonies on agar plates
with subinhibitory concentrations of each compound, colony
opacity was quantified using image analysis, and a quantitative
fitness score was assigned to each mutant based on differences in
colony opacity from the strain average (13). Positive fitness scores
reflect the degree of resistance of a mutant to an environmental
stress, and negative scores reflect the sensitivity to a stress. We use
“sensitivity profile” to refer to the set of fitness scores across all
mutants in the library for a particular stress condition.
The sensitivity profiles of holomycin, thiolutin, and gliotoxin
were correlated (R > 0.40, Pearson correlation coefficient with a
nonparametric cutoff yielding P < 0.05), reflecting a similar set
of genetic susceptibilities to these compounds in E. coli. In-
terestingly, the sensitivity profiles of these three compounds were
correlated to neither rifampicin nor actinomycin D (R < 0.05),
two antibiotics known to directly inhibit bacterial transcription.
Instead, hierarchical clustering of the dataset revealed that gene
deletion mutants in the acquisition of extracellular iron and zinc
were sensitized to all three compounds relative to the wild type
(hypersensitive mutants) (Fig. 2 and SI Appendix, Table S2).
The deleted genes in these hypersensitive mutants are primarily
located in two loci. The ent-fep locus encodes enzymes responsible
for both the biosynthesis of the iron siderophore enterobactin (ent
genes) and the transport machinery responsible for uptake of
extracellular ferric enterobactin (fep genes). The second locus is at
the znu operon that encodes an inner membrane zinc uptake
Fig. 1. Structures of disulfide-containing natural products. (A) Holomycin,
thiolutin, and gliotoxin are investigated using the chemical genomics screen.
(B) Our prior work suggests that holomycin is intracellularly converted to
reduced holomycin (red-holomycin) as the active form. The holomycin-pro-
ducing bacterium Streptomyces clavuligerus generates S,S’-dimethyl–red-
holomycin as a product of a backup protection mechanism, when the gene
encoding for dithiol oxidase HlmI is deleted.
Fig. 2. Chemical genomics screen identifies iron and zinc uptake mutants with increased sensitivity toward dithiolopyrrolones. Fitness scores of the chemical
genomics dataset were visualized as a heat map with 57 stress conditions (51 unique conditions) on the abscissa and Keio mutants on the ordinate. Stress
conditions described in this work are boxed in red including EDTA, gliotoxin, holomycin, and thiolutin. The dendrogram above the heat map represents
clustering of stress conditions with similar sensitivity profiles, which shows that holomycin and thiolutin cluster with two gliotoxin conditions (gtx-1 and gtx-2). The
rest of the conditions can be found in SI Appendix, Table S1, and their analysis is described in ref. 15. The first 12 conditions on the Left of the heat map are
conducted on iron-limited M9 minimal media, whereas the rest are on LB.
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complex. All three groups of genes were sensitized to holomycin,
thiolutin, and gliotoxin but not rifampicin or actinomycin D.
Instead, the sensitivity profiles of these compounds were more
similar to the metal chelator EDTA (Fig. 2), and are unique
among the ∼300 stress conditions tested in the previous and
present screens (12, 15). Given these shared sensitivity profiles in
metal uptake, we hypothesized that holomycin, thiolutin, and
gliotoxin exert antimicrobial activity by interfering with cellular
metal homeostasis.
Disrupting Metal Uptake Systems Sensitizes E. coli to Holomycin. We
validated the sensitivities of the E. coli mutants discovered in the
screen by an independent assay. At least one representative
deletion from each uptake pathway [zinc(II) and iron(III)] was
constructed in the E. coli MG1655 background using P1 trans-
duction and flippase recombinase (FLP)-mediated recombination
to excise the kanamycin resistance cassette (13). Holomycin was
chosen to represent the DTPs because it has a higher efficacy
against E. coli K-12 than thiolutin, and we have developed an
efficient synthetic route for holomycin. MOPS minimal medium
(MOPS MM) was used as a growth medium to control extracel-
lular metal content. Further, holomycin exhibits an order of
magnitude lower minimal inhibitory concentration (MIC) in
MOPS MM (0.2 μg/mL) liquid culture than in LB (2 μg/mL).
We used serial spot dilution assays to examine the sensitivities
of each deletion to holomycin. E. coli was initially grown in the
presence of 0.2 μg/mL holomycin; however, because MG1655
was less sensitive on solid media than in liquid culture, the
sensitivities of MG1655 and mutants were compared on con-
centrations from 0.1 to 0.4 μg/mL. The deletion mutants ΔentF,
ΔfepD, and ΔznuB were sensitive to 0.2 μg/mL of holomycin (SI
Appendix, Fig. S1A). Interestingly, the ΔfepA mutant has roughly
equal sensitivity to holomycin as MG1655 (SI Appendix, Fig.
S1A), potentially because E. coli harbor secondary receptors that
translocate iron-bound enterobactin degradation products (cat-
echols), which complement FepA function (16). Notably, growth
of the ΔznuB mutant is strongly inhibited even at a lower hol-
omycin concentration (0.1 μg/mL) (SI Appendix, Fig. S1A). In
contrast to the zinc import mutants, those in zinc export (ΔzntA,
ΔzntR) and regulation (Δzur) exhibit no change in sensitivity
relative to MG1655 (SI Appendix, Fig. S1A). Importantly, none
of the mutants showed growth defects in the absence of antibi-
otic (SI Appendix, Fig. S1B). The hypersensitivity of mutants
defective in iron and zinc import indicates that holomycin alters
intracellular metal availability, which the cell is unable to rectify
due to the mutations of these genes.
We chose to investigate the effect of holomycin on zinc ho-
meostasis because zinc uptake mutants were the most sensitive to
holomycin treatment among those identified from the chemical
genomics screen (SI Appendix, Fig. S1A). If cellular zinc seques-
tration is the primary effect of holomycin, complementation of
deletion strains with native levels of zinc import proteins should
rescue sensitivity to holomycin, and overexpression of entire zinc
transport complexes should enable resistance. Complementation
of ΔznuB by overexpression of znuB rescues the sensitivity of
ΔznuB without interfering with normal growth (SI Appendix, Fig.
S1 C–G). Furthermore, expression of the entire operon in both
wild type and ΔznuB allows E. coli MG1655 to resist a higher
concentration of holomycin (0.4 μg/mL) (SI Appendix, Fig. S1 F
and G). In this case the znuABC operon was introduced on a
multiple copy vector, which leads to enhanced expression of the
transporter complex, allowing E. coli to partly alleviate the zinc
homeostatic stress. To evaluate the effect of holomycin treatment
on the cellular zinc content, we conducted inductively coupled
plasma–mass spectrometry (ICP-MS) analysis on E. coli cells.
Cells treated with twice the MIC of holomycin retain a similar
cellular zinc quota within error (13 ± 2 ppb Zn/mg dry cells) as
those that are treated with DMSO vehicle alone (11.8 ± 0.3 ppb
Zn/mg dry cells) (SI Appendix, Fig. S2B). This result demon-
strates holomycin does not affect the total zinc content and
suggests that it may instead affect the cellular zinc availability.
Reduced Holomycin Chelates Zinc and Other Divalent Metals.We first
investigated the ability of holomycin to chelate essential metals,
focusing on zinc. Spectrophotometric and mass spectrometric
methods were used to examine the affinity of both the disulfide
and the reduced dithiol forms of holomycin (red-holomycin) for
several metal ions. We used 4-(2-pyridylazo)-resorcinol (PAR) as
a spectrophotometric binding competitor for zinc. Titration of
holomycin into the Zn(PAR)2 complex solution in the presence of
the reducing agents tris(2-carboxyethyl)phosphine (TCEP) or 1,4-
dithiothreitol (DTT) resulted in the loss of the characteristic Zn
(PAR)2 absorbance at 493 nm, indicating red-holomycin competes
with PAR for zinc binding (Fig. 3A and SI Appendix, Fig. S3). No
loss in the 493-nm peak is observed in the absence of reducing
agent, showing reduction of the DTP disulfide is required for zinc
chelation (SI Appendix, Fig. S4). DTT or TCEP alone could only
weakly dissociate the Zn(PAR)2 complex (SI Appendix, Fig. S3).
We characterized the formation of a potential Zn–red-holomycin
complex. In the PAR competition experiments, the decrease in
absorbance at 493 nm of the Zn(PAR)2 complex is accompanied by
an increase in a new absorbance band centered between 370 and
400 nm. Direct titration of zinc into red-holomycin resolves this
peak, which represents the newly formed complex with a λmax at
375 nm, distinct from the λmax of red-holomycin at 340 nm, with an
extinction coefficient of 30,840 M–1cm−1 (Fig. 3B). This titration also
shows an isosbestic point at 350 nm, suggesting only one species of
Zn–red-holomycin complex is formed, and it is related linearly
to red-holomycin. The absorbance of this complex reaches its
maximum at 0.5 equivalents of zinc, indicating a stoichiometry of
2:1 ligand:metal (L:M) (Fig. 3B), which has also been reported
for the reduced form of gliotoxin (17). A pH screen indicates
that the complex forms in a wide pH range (pH 4–10.5) based on
the characteristic 375-nm peak (SI Appendix, Fig. S5). High-
resolution mass spectrometry confirmed the stoichiometry and
the observed mass indicated that both ene-thiols exist in the
completely deprotonated thiolate form in the complex. Masses
corresponding to both [2M+Zn+H]–1 and [2M+Zn+Na]–1 (M =
red-holomycindithiolate or red–holo-dithiolate) were detected,
with distinct isotopic distributions for zinc (Fig. 3C). The exact
coordination chemistry is unknown and is depicted as tetrahedral
or octahedral as two possibilities (Fig. 3D).
Fig. 3. Reduced holomycin chelates zinc with high affinity. (A) Competition
experiment of reduced holomycin against Zn(PAR)2. PAR (blue) and Zn (II)
forms Zn(PAR)2 complex (red); titrations of 0–5 equivalents of reduced hol-
omycin (a gradient from gray to black) yield the Zn[red–holo-dithiolate]2
complex (black). (B) Direct titration of zinc into reduced holomycin leads to
formation of the Zn[red–holo-dithiolate]2 complex (λmax 375 nm). Holomycin
(blue) is converted to reduced holomycin (red) using TCEP; titrations of 0–1
equivalents of Zn(II) (a gradient from gray to black) yield the new complex
(black). The arrows in A and B indicate the direction of absorbance changes.
(C) Mass spectrum of the [2M+H+Zn]−1 complex with distinct isotopic dis-
tribution for Zn(II). (D) Two possible coordinations for the Zn[red–holo-
dithiolate]2 complex.














Based on the PAR competition data and the stoichiometry
obtained from mass spectrometry, we determined a stability
constant for the formation of the Zn[red–holo-dithiolate]2
complex. The average pKD’ (logβ’2) and SEM for complex for-
mation is 14.8 ± 0.1 based on three observations (stability con-
stant, 1014.8 ± 0.1 M−2) and corresponds to a pZn value of 11 (SI
Appendix). The pZn value for red-holomycin is in a similar range
as the pZn for EDTA we calculated (pZn = 15, SI Appendix).
These values demonstrate that red-holomycin binds zinc with
high affinity. red-Holomycin exhibits stronger chelating ability
compared with simple dithiol-containing compounds such as
DTT (SI Appendix, Fig. S3) or dihydrolipoic acid (SI Appendix,
Fig. S6), which may be due to lower pKa values or more rigid
geometry of the ene-dithiols than DTT and dihydrolipoic acid.
The aforementioned S,S’-dimethyl–red-holomycin, produced by a
holomycin biosynthetic mutant in S. clavuligerus, is unable to
chelate zinc, indicating that the free ene-dithiol is essential for zinc
binding (SI Appendix, Fig. S7). This result is consistent with the
lack of antimicrobial activity of this compound against Strepto-
myces spp. and further supports that S-methylation is a general
mechanism for self-protection by microbial producers of disulfide-
containing natural products such as DTPs and gliotoxin (10, 18).
Holomycin also forms complexes with Cu(I) and Fe(II). By direct
titration of Fe(II) or Cu(I) into red-holomycin, we observed a λmax
centered around 379 nm and 386 nm for red-holomycin com-
plexed with Fe(II) and Cu(I), respectively (SI Appendix, Figs. S8
and S9). We focus on zinc chelation in the rest of this study
because the E. coli mutants deficient in zinc uptake are most
sensitive to holomycin, as described above.
Prodrug Mechanism of Holomycin. We have previously proposed
that holomycin is a prodrug that is intracellularly reduced to its
active form (10). To validate this mechanism, we examined
whether the reduced and metallated forms of holomycin can in-
hibit bacterial growth. Preformed red-holomycin or Zn[red-holo]2
complex added extracellularly display much weaker antibacterial
activity than the disulfide form of holomycin as shown by a disk
diffusion assay (SI Appendix, Fig. S2A), suggesting that both the
reduced and metallated forms of holomycin are insufficiently
taken up by the bacteria. In addition, the Zn[red-holo]2 complex,
once formed, is stable in the presence of physiologically relevant
ligands, such as glutathione (both reduced and oxidized), citric
acid, and cysteine (SI Appendix, Fig. S10). Together these results
strongly indicate that holomycin enters the cell in the disulfide
form as a prodrug, and the resulting reduced form acts as an
intracellular chelator and yields a stable complex inside the cell.
This proposed prodrug mechanism is reminiscent of the disul-
fide-containing natural product FK228, which undergoes intra-
cellular reduction in a glutathione-dependent manner, unmasking
an alkyl thiolate that ligands to zinc in histone deacetylases (19).
Holomycin joins FK228 as a redox-controlled zinc-liganding
natural product.
Holomycin Inhibits FbaA but not E. coli RNA Polymerase in Vitro.
RNA polymerase contains structural zinc ions, the chelation of
which has been proposed as the antimicrobial mechanism for the
natural product lomofungin (20, 21). To examine whether hol-
omycin inhibits RNA polymerase via a similar chelation mech-
anism and resolve the conflicting reports regarding RNA
polymerases as targets for DTPs, we reevaluated the activity of
red-holomycin against purified E. coli RNA polymerase in vitro
using a [α-32P] CTP transcription assay. We observed less than
20% inhibition of E. coli RNA polymerase by up to 100 μM
(∼20 μg/mL) red-holomycin but complete inhibition by 50 μM
rifampicin, a RNA polymerase inhibitor (SI Appendix, Fig. S2C).
This result is in agreement with the prior report by Oliva et al.
(8) on the weak inhibition of RNA polymerase by holomycin
under reducing conditions containing DTT and demonstrates that
RNA polymerase is unlikely the primary antimicrobial target of
holomycin in E. coli. Inhibition of yeast RNA polymerase reported
for thiolutin may result from inhibiting zinc-dependent transcription
factors in the eukaryotic preinitiation complex, which is absent in
prokaryotes, rather than RNA polymerase itself.
To explore the ability of holomycin to inhibit metalloproteins,
we evaluated the class II zinc-dependent fructose bisphosphate
aldolase (FbaA) as a holomycin target because it is essential for
E. coli growth and has already been explored as an antimicrobial
target due to its general absence from plants and animals (22).
Using a coupled spectrophotometric assay that measures NADH
consumption, we showed that red-holomycin inhibits 85–90% of
FbaA activity at 25 μM (SI Appendix, Fig. S11). This result
suggests that inhibition of FbaA contributes to the overall in-
hibitory effect of holomycin. Inhibition of FbaA also explains the
previously observed phenotypes for thiolutin treatment of E. coli:
thiolutin prevents glucose utilization while permitting growth on
glycerol, lactate, succinate, or fumarate, all of which enter me-
tabolism downstream of FbaA (9). Furthermore, inhibition of
glycolysis would result in ppGpp accumulation and a decrease in
initiating nucleotide triphosphate (iNTP). This situation can lead
to the stringent response and inhibition of RNA synthesis, as has
been observed for holomycin (8, 9, 23). The inhibition of FbaA but
not RNA polymerase suggests that holomycin, despite its small
size, selectively targets a subset of metalloproteins. Metal chela-
tion in metalloproteins by holomycin provides a unified mecha-
nism for the inhibition of the multiple pathways previously
reported; transcription is unlikely the primary target of holomycin
and may only represent a component of the downstream effects.
Holomycin Inhibits Metallo–β-Lactamases in Vitro. Due to the high
affinity of red-holomycin for zinc and its inhibition of FbaA, we
investigated the utility of holomycin against other therapeutically
relevant metalloproteins. As a proof of concept, we examined
the inhibitory activity of holomycin against a metallo–β-lactamase
(MBL), New Delhi MBL-1 (NDM-1). MBLs are a significant
clinical health threat due to their ability to confer antimicrobial
resistance by hydrolyzing all types of β-lactams, including “last-
resort” carbapenems (24). Importantly, MBLs use a zinc-
dependent catalytic mechanism that is distinct from serine hy-
drolase β-lactamases and are therefore resistant to the clinically
used β-lactamase inhibitor clavulanic acid. We monitored the
activity of reconstituted NDM-1 by the hydrolysis of imipenem
and nitrocefin, two well-established substrates for NDM-1 (Fig. 4
Fig. 4. Inhibition of NDM-1 by reduced holomycin. (A) Hydrolysis reaction
of imipenem carried out by NDM-1. (B) Treatment of NDM-1 with red-hol-
omycin decreases the number of zinc equivalents (Eq) in NDM-1 as detected
by ICP-MS, error bars denote SEM of biological quadruplicate data. (C) Dose–
response curve of 250 pM NDM-1 treated with varying concentrations of
holomycin. Error bars represent SEM of three replicates. (D) The hydrolysis of
imipenem by NDM-1 is inhibited by 5 μM reduced holomycin (red); NDM-1
activity can be restored upon addition of 4x molar excess Zn(II) (relative to
holomycin) at 15 min (*). Neither the disulfide form of holomycin (purple)
nor TCEP and DMSO vehicle (blue) inhibits imipenem hydrolysis by NDM-1.
2720 | www.pnas.org/cgi/doi/10.1073/pnas.1612810114 Chan et al.
A and C and SI Appendix, Fig. S12) (24). Preincubation of red-
holomycin with NDM-1 inhibited hydrolysis of both imipenem
and nitrocefin (Fig. 4C and SI Appendix, Fig. S12). The dose–
response curve of red-holomycin against NDM-1 yielded an IC50
of 110 nM for imipenem and 153 nM for nitrocefin, demon-
strating its high potency.
We next investigated the mechanism of NDM-1 inhibition by
red-holomycin. NDM-1 contains two active site zincs and requires
at least one for imipenem hydrolysis (25). We reconstituted NDM-1
with zinc and removed unbound zinc by buffer exchange. ICP-MS
analysis of reconstituted NDM-1 confirmed that 2.7 ± 0.4 equiv-
alents of zinc are bound to NDM-1. After red-holomycin treat-
ment, only 0.6 ± 0.3 equivalents of zinc remain bound to NDM-1,
indicating that red-holomycin has removed 2.1 ± 0.5 equivalents of
zinc from NDM-1 (Fig. 4B and SI Appendix, Table S3). In addition,
inhibition of NDM-1 by red-holomycin is reversible by the addition
of four times excess ZnSO4 relative to holomycin (Fig. 4D). These
results indicate that red-holomycin inhibits NDM-1 reversibly by
removing active site zinc. Previous reports show that EDTA
removes both zinc ions, and PAR only removes one zinc from
NDM-1 (25). The zinc-binding affinity of red-holomycin is lower
than EDTA but higher than PAR, thus corroborating its ability to
remove zinc from NDM-1. A similar mechanism of zinc metal-
loenzyme inhibition has also been reported for gliotoxin, which
ejects zinc from p300 and blocks the HIF-1α-mediated hypoxic
response (26). As expected, the disulfide form of holomycin does
not inhibit NDM-1 because it lacks the ability to chelate zinc (Fig.
4D). These results demonstrate that red-holomycin is a potent in-
hibitor of NDM-1 through a zinc chelation mechanism.
A Model for Holomycin Action. We propose a model for the anti-
microbial action of holomycin: holomycin enters target bacteria
as the disulfide form and is reductively activated in the cyto-
plasm; reduced holomycin likely redistributes the metal pool by
sequestering free metal ions (route 1) and removing metals from
a subset of metalloproteins (route 2); these two actions enable
holomycin to inhibit multiple essential pathways simultaneously
(Fig. 5). Metal ions are essential for bacterial growth, and the
disruption of metal homeostasis has profound impacts on via-
bility (27). Route 1 is based on the high-affinity chelating activity
of holomycin and the increased bacterial resistance to holomycin
when zinc import genes are overexpressed (SI Appendix, Fig. S1
C–G). Although bacteria maintain zinc at a relatively high total
concentration (between 0.1 and 0.2 mM), little intracellular iron
or zinc exists as free metal ions (free zinc concentration in E. coli
between 2.0 and 11.5 × 10−16 M) (28, 29). Sequestration of this
labile zinc pool by holomycin can have dramatic impacts on zinc
homeostasis. Route 2 is in accordance with our in vitro findings
on the direct inhibition of essential metalloproteins such as FbaA.
Rather than directly impacting proteins involved in the mainte-
nance of metal homeostasis, such as the zinc uptake machinery
ZnuABC that we identified by chemical genomics (Fig. 5), hol-
omycin likely targets essential proteins that depend on metal for
activity. This route may be more prominent in the mode of action,
as supplementation with higher concentrations of zinc does not
alleviate growth inhibition by holomycin (SI Appendix, Fig. S2 and
Table S4), in contrast to the deactivation of extracellular chelators
like EDTA by exogenous metals. Although a significant portion of
cellular zinc is thought to bind RNA polymerase and ribosomal
proteins, the most abundant proteins in the cell (28, 30), a great
deal remains unknown about zinc homeostasis, such as zinc dis-
tribution in the cell and mechanisms of zinc trafficking and in-
sertion into proteins (31). These observations lay the foundation
for future efforts to understand the specificity of holomycin and
other DTPs against metalloproteins.
Implications for Antimicrobial Therapy. The classic function of
metallophores and siderophores is the acquisition of essential
metals; however, additional functions for natural product met-
allophores have emerged in microbe–microbe and microbe–host
interactions in recent years (32), including protection from host
defenses (33), and cell–cell communication and signaling (34).
Although many natural products bind metals, only a few have
been reported to exhibit antimicrobial activity, including the
aforementioned lomofungin (20) and actinonin, which has been
explored as an inhibitor of polypeptide deformylase (35). Our
studies of holomycin suggest that DTPs are a unique class of
intracellular metallophores that function as potent antibiotics.
The structural and activity distinction of holomycin from lomo-
fungin, actinonin, and gliotoxin (SI Appendix, Fig. S13) indicates
that nature has evolved diverse chemical scaffolds all with che-
lating ability but diverse targets.
Although metal homeostasis has been explored as an antimi-
crobial target, prior efforts have primarily focused on the inhibition
of metal uptake, specifically, the biosynthesis of siderophores (36).
Many pathogens, however, produce multiple siderophores, dimin-
ishing the efficacy of any single inhibitor (37). Our work further
supports that direct chelation of metal ions can simultaneously
alter metal availability and interfere with essential metal-
loprotein-dependent cellular processes; such effects have been
reported for metal chelators in targeting bacterial infections,
cancer, and neurodegenerative disorders (38, 39). This multi-
faceted strategy decreases the likelihood of bacterial resistance.
Consistent with this hypothesis, only mutants with two- to four-
fold increases in resistance were obtained in attempts to raise
spontaneous suppressor mutants against holomycin in E. coli in
LB (SI Appendix). These mutants contain loss-of-function muta-
tions in glutathione biosynthesis, consistent with the prodrug
mechanism of holomycin; however, glutathione alone cannot re-
duce holomycin in vitro (SI Appendix, Fig. S14), suggesting addi-
tional mechanisms are involved in the intracellular activation of
holomycin. The cytotoxicity of DTPs against human cell lines may
complicate the use of DTPs in antimicrobial therapies, but it also
suggests the medicinal applications of DTPs may extend beyond
antimicrobial therapy (2).
The potent and reversible inhibition of MBLs by red-holomycin
identifies DTP as a potential scaffold to inhibit carbapenem re-
sistance by MBLs. Holomycin joins the natural product aspergil-
lomarasmine A (AMA) (40) and the synthetic spiro-indoline–
thiadiazoles (41) and the bisthiazolidines (42) as MBL inhibitors
via a zinc-chelation mechanism. Both AMA and SIT-Z5 resensi-
tized NDM-1 positive K. pneumoniae to carbapenem antibiotics
(40, 41), revealing the promise of zinc chelators as carbapenem
potentiators. Although red-holomycin potently inhibits NDM-1
in vitro, the effects of holomycin and meropenem are additive in
whole-cell assays against NDM-1 positive K. pneumoniae (SI
Appendix, Fig. S15). This effect is likely due to the cellular lo-
calization of NDM-1 in the oxidizing periplasm of Gram-negative
bacteria that does not allow reductive activation of holomycin.
Fig. 5. A model for the mechanism of action of holomycin. Holomycin is
internalized as a prodrug by a target bacterium such as E. coli, and reductive
activation in the cytoplasm generates red-holomycin, which disrupts zinc
homeostasis by two possible routes: (1) red-holomycin chelates labile zinc
and limits zinc availability; (2) red-holomycin chelates and removes zinc from
a subset of zinc-dependent enzymes, inactivation of which have a multitude
of impacts such as inhibition of glucose utilization, RNA synthesis, and respi-
ration. Although both routes contribute to the inhibitory effect of holomycin,
route 2 is likely more prominent. Disruption of the zinc import machinery
ZnuABC restricts zinc uptake and further sensitizes E. coli to holomycin.














Consequently, holomycin cannot inhibit periplasmic NDM-1 be-
fore entry to the cytoplasm. This result further supports that
holomycin is selective for cytoplasmic metal chelation. Further,
holomycin differs from other zinc-chelating inhibitors in two major
ways: holomycin is a potent antibiotic, whereas the other inhib-
itors harbor little antimicrobial activity alone; holomycin also has
a distinctive zinc coordination and binding mode: two red-hol-
omycin molecules likely supply four thiolates and potentially two
carbonyl ligands, whereas the other inhibitors use a combination
of thiol, carboxylic acid, and nitrogen ligands. These unique
chelating properties promote DTP natural products as a starting
point for developing scaffolds to inhibit MBLs and other thera-
peutically relevant zinc-dependent enzymes.
Conclusion
We have connected the chemical activities of DTPs with their
mechanisms of action. Holomycin acts as a prodrug, whose in-
tracellular reduction facilitates high-affinity chelation with metal
ions, particularly zinc. Chelation allows holomycin to disrupt
metal homeostasis and inhibit bacterial growth by inhibiting a
subset of metalloenzymes. As an application and exploitation of
this activity, we show that holomycin potently inhibits the
β-lactam resistance enzyme NDM-1 in vitro. Our work highlights
that systematic mode-of-action studies are critical to understand
how antibiotics function and to revive the therapeutic potential
of previously neglected antibiotics.
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